Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
iShares U.S. Pharmaceutical ETF
(NY:
IHE
)
86.33
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EST, Jan 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about iShares U.S. Pharmaceutical ETF
< Previous
1
2
3
Next >
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
↗
December 19, 2024
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.
Via
Benzinga
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares
↗
December 13, 2024
Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase.
Via
Benzinga
Topics
ETFs
FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'
↗
November 13, 2024
FDA Chief Robert Califf reflects on potential changes as Trump's re-election looms, expressing disappointment and highlighting uncertainty within the agency.
Via
Benzinga
Topics
Government
3 Sector ETFs That Beat The Market Last Week
↗
August 14, 2023
Here are three ETFs from different sectors that were in green last week.
Via
Talk Markets
Topics
ETFs
US Pharmaceuticals: A Bifurcated Market
↗
January 12, 2022
The US pharmaceutical industry faces two important goals that conflict with each other.
Via
Talk Markets
Trump Has Asked Me To Do 3 Things, Says Robert Kennedy Jr.
↗
November 06, 2024
Robert Kennedy Jr. revealed Trump's directive to tackle health agency corruption, promote science, and end chronic disease.
Via
Benzinga
Topics
Government
A Look At Pharma ETFs Post Q1 Earnings
↗
May 07, 2024
Pharma ETFs have delivered mixed performances over the past month.
Via
Talk Markets
Topics
ETFs
ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook
↗
May 01, 2024
Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest...
Via
Talk Markets
Topics
ETFs
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
↗
February 26, 2024
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.
Via
Benzinga
A Look At Pharma ETFs After Q4 Earnings
↗
February 12, 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.
Via
Talk Markets
Topics
ETFs
April Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy Market
↗
April 30, 2024
Performance in April 2024: Utilities lead, real estate lags. S&P 500, Nasdaq 100, Dow Jones Industrial Average, small-cap and large-cap indices all decline.
Via
Benzinga
Topics
Stocks
Bank Of America Predicts 10 2024 Market Surprises: From Booming IPOs To Japanese Equity Surge
↗
January 09, 2024
Bank of America lists 10 market surprises; warns investors to be wary of the bond market's dovish position compared to the Fed.
Via
Benzinga
Topics
Bonds
3 Beaten-Down ETFs To Buy For A Turnaround In 2024
↗
December 22, 2023
Following three consecutive monthly losses since the COVID pandemic began in March 2020, Wall Street recorded a robust recovery starting in November. we have highlighted ETFs from different zones that...
Via
Talk Markets
Topics
ETFs
5 Secret Santa ETFs That Might Surprise You This Christmas
↗
December 16, 2023
Wall Street has been sizzling hot this holiday season. This is likely to continue, given that the Santa Claus rally is on the way. Against such a backdrop, there are some hidden gems which could...
Via
Talk Markets
Topics
ETFs
Pharmacy Workers Strike At CVS and Walgreens, Echoing Wider Pharma Sector Unrest
↗
November 05, 2023
In a recent surge of labor unrest, pharmacy employees from CVS Health Corporation (NYSE: CVS) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA) raised their voices by calling out sick or walking out...
Via
Benzinga
5 Sector ETFs That Outperformed in Turbulent August
↗
August 30, 2023
Wall Street has lost momentum since the start of August, triggered by the series of bank downgrades and fears of higher rates for a longer-than-expected period.
Via
Talk Markets
Topics
ETFs
Q2 Earnings & Market Sell-Off Impact: 5 Must-See ETF Charts
↗
August 25, 2023
While longer-than-expected rate worries and banking concerns led to feeble trading in recent weeks, a few equity ETFs rose or saw a modest decline over the past month.
Via
Talk Markets
Topics
ETFs
Pharma ETFs in Focus Post Q2 Earnings
↗
August 11, 2023
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth.
Via
Talk Markets
Topics
ETFs
3 Biotech Stocks to Sell in June Before They Crash and Burn
↗
June 06, 2023
Investors should get out of these biotech stocks to sell now that the Covid-19 pandemic is largely over. These's worse in store for them.
Via
InvestorPlace
Pharma ETFs Gain Post Q1 Earnings
↗
May 09, 2023
Pharma ETFs have been in the green over the past month.
Via
Talk Markets
A Look At Pharma ETFs Post Q4 Earnings
↗
February 08, 2023
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month.
Via
Talk Markets
4 Sector ETFs To Watch Ahead Of Mid-Election Results
↗
November 10, 2022
Some market analysts are signaling that a political gridlock by Republicans may be a positive for Wall Street and the U.S. economy.
Via
Talk Markets
5 ETFs To Watch After 2022 Midterm Elections: Which Sectors Win From Republican Or Democrat Majority?
↗
November 09, 2022
The 2022 election was held on Tuesday, Nov. 8. No decision has been made as to who won many of the key battles, including several pivotal seats in the U.S. House of Representatives and U.S. Senate.
Via
Benzinga
Pharma ETFs In Focus Post Q3 Earnings
↗
November 09, 2022
Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month.
Via
Talk Markets
ETF Mid-Year Outlook & Investing Strategies
↗
July 22, 2022
While positioning the portfolio for the second half investors should focus on three themes: 1) embracing volatility, 2) living with inflation, and 3) the long-term impacts of shortages.
Via
Talk Markets
Wave of Solid Q3 Earnings Push Pharma ETFs Higher
↗
November 09, 2021
The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.
Via
Talk Markets
J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data
↗
September 25, 2021
Johnson & Johnson has again announced positive data highlighting the efficiency of its single-shot COVID-19 vaccine in providing protection against COVID-related hospitalizations.
Via
Talk Markets
Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?
↗
September 24, 2021
Investors have one more reason to cheer the COVID-19 vaccine update as the FDA has approved emergency use of a booster dose of the Pfizer Inc. and BioNTech SE COVID-19 vaccine.
Via
Talk Markets
3 Dividend-Paying Pharmaceutical Stocks to Buy This Summer
↗
June 05, 2021
The pharmaceutical industry has benefited from much investor attention amid the COVID-19 pandemic.
Via
Talk Markets
Tuesday Talk: Slip Sliding Sideways
↗
May 18, 2021
With the Middle East seemingly going to Hell in a proverbial handbasket the markets seem to be slip sliding, not away (as the Paul Simon song would have it) sideways as it were.
Via
Talk Markets
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.